OMEZA Holdings and Spartan Medical Partner on Wound Care Product
OMEZA Holdings and Spartan Medical have entered into an exclusive partnership that will provide OMEZA's OCM™ wound care product to U.S. military personnel, veterans, and Indian Health Services beneficiaries.
Sarasota, Florida – OMEZA Holdings and Spartan Medical announced today an exclusive partnership that will make OMEZA's OCM™ product available to active U.S. military personnel, veterans, and beneficiaries of the Indian Health Services (IHS).
The OCM™ is an FDA-cleared wound matrix derived from marine lipids and cold-water fish peptides. It is designed to reduce inflammation, disrupt bacterial biofilms, and support tissue regeneration, offering a cost-effective alternative to traditional skin grafts. Spartan Medical, a veteran-owned government contractor, will facilitate the distribution and ordering processes for these beneficiaries within the U.S. Department of Veterans Affairs and the U.S. Department of Defense.
"Spartan Medical has built its wound care portfolio 'brick by brick' to bring the most advanced medical technologies to our Veterans and Service Members," said Vince Profitt, Founder and President of Spartan Medical. "OMEZA's OCM™ is an outstanding addition, ready now, to deploy across the federal marketplace."
OMEZA Holdings manufactures its products in the USA. This collaboration aims to enhance wound care and cost-efficiency for targeted patient populations serving U.S. interests globally.